Phase II trial of N-methylformamide in advanced head and neck cancer

Walter C. Vogel, Arlene A. Forastiere, Ronald B. Natale, Bonnie J. Takasugi, Gary Schnur

Research output: Contribution to journalArticlepeer-review

Abstract

Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

Original languageEnglish (US)
Pages (from-to)203-206
Number of pages4
JournalInvestigational New Drugs
Volume5
Issue number2
DOIs
StatePublished - Jun 1987

Keywords

  • N-methylformamide
  • head and neck cancer
  • phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of N-methylformamide in advanced head and neck cancer'. Together they form a unique fingerprint.

Cite this